References
- Maron BJ, Desai MY, Nishimura RA, et al. Management of hypertrophic cardiomyopathy: JACC state-ofthe-art review. J Am Coll Cardiol 2022;79:390-414. https://doi.org/10.1016/j.jacc.2021.11.021
- Lee HJ, Kim J, Chang SA, Kim YJ, Kim HK, Lee SC. Major clinical issues in hypertrophic cardiomyopathy. Korean Circ J 2022;52:563-75. https://doi.org/10.4070/kcj.2022.0159
- Park CS, Rhee TM, Lee HJ, et al. Prognostic and safety implications of renin-angiotensin-aldosterone system inhibitors in hypertrophic cardiomyopathy: a real-world observation over 2,000 patients. Korean Circ J 2023;53:606-18. https://doi.org/10.4070/kcj.2023.0035
- Youn JC, Kim D, Cho JY, et al. Korean Society of Heart Failure guidelines for the management of heart failure: treatment. Korean Circ J 2023;53:217-38. https://doi.org/10.4070/kcj.2023.0047
- Zhang Y, Liu MH, Zhang M, et al. Different clinical characteristics and outcomes of hypertrophic cardiomyopathy with and without hypertension: seeking the truth. J Geriatr Cardiol 2023;20:109-20. https://doi.org/10.26599/1671-5411.2023.02.007
- Ho CY, Day SM, Axelsson A, et al. Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Nat Med 2021;27:1818-24. https://doi.org/10.1038/s41591-021-01505-4
- Kim KH, Pereira NL. Genetics of cardiomyopathy: clinical and mechanistic implications for heart failure. Korean Circ J 2021;51:797-836. https://doi.org/10.4070/kcj.2021.0154